• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.05% Nasdaq Down0.18%

    More On PRR.AX

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Prima Biomed Ltd. (PRR.AX)

    -ASX
    0.04 0.00(0.00%) 2:10AM EDT
    ProfileGet Profile for:
    Prima Biomed Ltd.
    95 Pitt Street
    Level 12
    Sydney, NSW 2000
    Australia - Map
    Phone: 61 2 8315 7003
    Fax: 61 2 8569 1880
    Website: http://www.primabiomed.com.au

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:N/A

    Business Summary 

    Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of cancer. Its lead product candidate is IMP321, a recombinant protein, which is in phase II clinical trials in metastatic breast cancer when used as a chemo-immunotherapy. The company’s other products include IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. It also develops CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The company has collaboration with NEC Corporation and Yamaguchi University. Prima BioMed Ltd. is based in Sydney, Australia.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Prima Biomed Ltd.

    Key Executives 
     PayExercised
    Mr. Marc Voigt , 43
    Chief Exec. Officer, Chief Financial Officer, Chief Bus. Officer, Exec. Director, Member of Audit & Risk Committee and Member of Remuneration Committee
    345.00KN/A
    Dr. Frédéric Triebel M.D., Ph.D., 61
    Chief Scientific Officer and Chief Medical Officer
    130.00KN/A
    Ms. Deanne Miller LLB, 39
    Gen. Counsel and Company Sec. (Leave of absence)
    259.00KN/A
    Mr. Thomas Robert John Bloomfield BA (Hons), ACIS, MAICD,
    Joint Company Sec.
    N/AN/A
    Ms. Larisa Chisholm ,
    Director of Industry Liaison & Devel. and Director of Intellectual Property
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in AUD.